Before revision: Centrally acting dopamine D1-like receptor agonists like tavapadon (CVL-751, PF-06649751) , and razpipadon (CVL-871) and D1 receptor positive modulators like mevidalen (LY-3154207) and glovadalen (UCB-0022) are also under development for medical use, including treatment of Parkinson's disease and notably of dementia-related apathy.
After revision: Centrally acting dopamine D1-like receptor agonists like tavapadon (CVL-751 PF-06649751) , and razpipadon (CVL-871) and D1 receptor positive modulators like mevidalen (LY-3154207) and glovadalen (UCB-0022) are also under development for medical use, including treatment of Parkinson's disease and notably of dementia-related apathy.